Free Trial
NASDAQ:NRXP

NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis

NRx Pharmaceuticals logo
$2.01 +0.07 (+3.61%)
Closing price 04:00 PM Eastern
Extended Trading
$2.02 +0.02 (+0.75%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NRx Pharmaceuticals Stock (NASDAQ:NRXP)

Key Stats

Today's Range
$1.89
$2.07
50-Day Range
$1.94
$3.55
52-Week Range
$1.10
$6.01
Volume
166,676 shs
Average Volume
450,884 shs
Market Capitalization
$34.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.25
Consensus Rating
Buy

Company Overview

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Remove Ads

NRx Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

NRXP MarketRank™: 

NRx Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 491st out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NRx Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about NRx Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for NRx Pharmaceuticals are expected to grow in the coming year, from ($1.75) to ($0.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NRx Pharmaceuticals is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NRx Pharmaceuticals is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about NRx Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.34% of the float of NRx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    NRx Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NRx Pharmaceuticals has recently decreased by 11.97%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    NRx Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    NRx Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.34% of the float of NRx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    NRx Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NRx Pharmaceuticals has recently decreased by 11.97%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    NRx Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for NRx Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    10 people have searched for NRXP on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added NRx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.00% of the stock of NRx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 4.27% of the stock of NRx Pharmaceuticals is held by institutions.

  • Read more about NRx Pharmaceuticals' insider trading history.
Receive NRXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NRXP Stock News Headlines

NRx Pharmaceuticals (NRXP) to Release Earnings on Friday
DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
NRx Pharmaceuticals’ Hope Therapeutics to acquire Dura Medical, no terms
Equities Analysts Offer Predictions for NRXP FY2025 Earnings
NRx Pharmaceuticals, HOPE Therapeutics sign binding LOI with Neurospa
See More Headlines

NRXP Stock Analysis - Frequently Asked Questions

NRx Pharmaceuticals' stock was trading at $2.20 at the start of the year. Since then, NRXP stock has decreased by 7.7% and is now trading at $2.03.
View the best growth stocks for 2025 here
.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced its earnings results on Friday, March, 14th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.10.

Shares of NRx Pharmaceuticals reverse split on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NRx Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), Meta Platforms (META), General Electric (GE) and Disc Medicine (IRON).

Company Calendar

Last Earnings
3/14/2025
Today
4/02/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NRXP
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.67
High Stock Price Target
$45.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+1,562.3%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-30,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($1.38) per share
Price / Book
-1.38

Miscellaneous

Free Float
12,717,000
Market Cap
$32.22 million
Optionable
Optionable
Beta
1.22
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:NRXP) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners